TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseasesChi Young Ok, Sa A. Wang, L. Jeffrey Medeiros et al.|Journal of Hematology & Oncology|2015Cited by 142
Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseasesChi Young Ok, Sa A. Wang, Bin Fu et al.|Leukemia Research|2014Cited by 128
Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (<scp>MCL</scp>) ‐ outcomes and mutation profile from venetoclax resistant <scp>MCL</scp> patientsShuangtao Zhao, Preetesh Jain, C. Cameron Yin et al.|American Journal of Hematology|2020Cited by 84
Persistent <i>IDH1/2</i> mutations in remission can predict relapse in patients with acute myeloid leukemiaChi Young Ok, Keyur P. Patel, L. Jeffrey Medeiros et al.|Haematologica|2018Cited by 82
Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell LymphomaPreetesh Jain, Michael Wang, L. Jeffrey Medeiros et al.|Journal of Clinical Oncology|2021Cited by 82